Efficacy of R‐BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy-Reference-Cited by-同舟云学术

Efficacy of R‐BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy

Published:2020-02-03 Issue:4 Volume:189 Page:684-688
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

McCulloch Rory¹^ORCID,Visco Carlo²^ORCID,Eyre Toby A.³,Frewin Rebecca⁴,Phillips Neil⁵,Tucker David L.⁶,Quaglia Francesca M.²,McMillan Annabel⁷,Lambert Jonathan⁷,Crosbie Nicola¹,Rule Simon¹⁸

Affiliation:

1. Department of Haematology University Hospitals Plymouth NHS Trust Plymouth UK

2. Department of Medicine Section of Hematology University of Verona Verona Italy

3. Department of Haematology Oxford University Hospitals NHS Foundation Trust Oxford UK

4. Department of Haematology Gloucestershire Hospitals NHS Foundation Trust Gloucester UK

5. Department of Haematology University Hospitals of North Midlands NHS Trust Stoke‐on‐Trent UK

6. Department of Haematology Royal Cornwall Hospitals NHS Trust Truro UK

7. Department of Haematology University College London Hospitals NHS Foundation Trust London UK

8. Peninsula Medical School University of Plymouth Plymouth UK

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16416

Reference14 articles.

1. Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study

2. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes

3. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

4. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties

5. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study;Blood;2024-08-29

2. Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis;Leukemia & Lymphoma;2024-07-08

3. Real-World Evidence of Relapsed/Refractory Mantle Cell Lymphoma Patients and Treatments: A Systematic Review;Journal of Blood Medicine;2024-05

4. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor;Advances in Therapy;2024-03-18

5. Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study;Annals of Hematology;2024-02-03